Pathological Complete Response in Metastatic Renal Cell Carcinoma Patients Treated With Cabozantinib Plus Nivolumab. Case Series and Literature Review

IF 2.3 3区医学 Q3 ONCOLOGY

Clinical genitourinary cancer Pub Date : 2025-03-07 DOI:10.1016/j.clgc.2025.102328

Marco Stellato MD , Simone Rota MD , Melanie Claps MD , Valentina Guadalupi MD , Alessandro Rametta MD , Giuseppe Fotia MD , Marco Barella MD , Elena Verzoni MD , Giuseppe Procopio MD

引用次数: 0

Abstract

•
Cabozantinib plus nivolumab could be safe and effective in metastatic Renal Cell Carcinoma patients with oligometastatic disease and primary in site.
•
IO-TKI is associated to high response rate that sometimes includes pathological Complete Response.
•
Cytoreductive Nephrectomy should be considered in multidisciplinary team as an option for selected patients with low disease burden, fit for surgery, especially following a favorable response to systemic treatment.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical genitourinary cancer 医学-泌尿学与肾脏学

CiteScore

5.20

自引率

6.20%

发文量

201

审稿时长

54 days

期刊介绍： Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.